Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Taiwanese (TAIEX) Healthcare Sector Analysis

UpdatedJan 02, 2026
DataAggregated Company Financials
Companies223
  • 7D-0.9%
  • 3M-8.8%
  • 1Y7.0%
  • YTDn/a

Over the last 7 days, the Healthcare industry has remained flat, although notably Center Laboratories gained 12%. As for the the longer term, the industry is up 7.0% over the past 12 months. Earnings are forecast to grow by 61% annually.

Sector Valuation and Performance

Has the Taiwanese Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 02 Jan 2026NT$1.7tNT$267.4bNT$13.6b18.8x123.2x6.3x
Sun, 30 Nov 2025NT$1.8tNT$267.8bNT$13.1b20.3x134.4x6.6x
Tue, 28 Oct 2025NT$1.8tNT$266.9bNT$8.2b21.6x215.7x6.7x
Thu, 25 Sep 2025NT$1.8tNT$266.0bNT$8.2b22.6x219.1x6.8x
Sat, 23 Aug 2025NT$1.8tNT$266.4bNT$9.2b21.7x193.2x6.7x
Mon, 21 Jul 2025NT$1.6tNT$261.0bNT$16.4b20.2x99x6.2x
Wed, 18 Jun 2025NT$1.6tNT$260.9bNT$16.3b19.8x95.9x6x
Fri, 16 May 2025NT$1.5tNT$261.7bNT$16.3b21.1x90.2x5.6x
Sun, 13 Apr 2025NT$1.3tNT$254.3bNT$12.0b18.5x110.5x5.2x
Tue, 11 Mar 2025NT$1.6tNT$250.9bNT$12.2b23.6x132.9x6.5x
Thu, 06 Feb 2025NT$1.6tNT$246.5bNT$8.4b22.8x187.8x6.4x
Sat, 04 Jan 2025NT$1.5tNT$245.2bNT$8.6b22.1x173.8x6.1x
Mon, 02 Dec 2024NT$1.6tNT$244.7bNT$9.1b22.5x172.7x6.4x
Wed, 30 Oct 2024NT$1.5tNT$236.6bNT$6.9b25.5x221x6.5x
Fri, 27 Sep 2024NT$1.6tNT$236.4bNT$6.8b24.9x231.5x6.6x
Sun, 25 Aug 2024NT$1.6tNT$236.8bNT$6.8b25.8x237.9x6.9x
Tue, 23 Jul 2024NT$1.6tNT$229.1bNT$3.7b29.6x438.7x7.1x
Thu, 20 Jun 2024NT$1.6tNT$228.6bNT$3.9b27.2x397.7x6.8x
Sat, 18 May 2024NT$1.5tNT$230.2bNT$5.8b26.5x258.8x6.5x
Mon, 15 Apr 2024NT$1.5tNT$228.3bNT$4.6b26.4x336.4x6.8x
Wed, 13 Mar 2024NT$1.4tNT$226.2bNT$7.1b25.3x204.1x6.4x
Fri, 09 Feb 2024NT$1.4tNT$225.8bNT$6.5b24.7x215.6x6.2x
Sun, 07 Jan 2024NT$1.4tNT$224.9bNT$6.0b25.5x235.1x6.3x
Tue, 05 Dec 2023NT$1.4tNT$224.7bNT$5.9b25.7x245.5x6.5x
Thu, 02 Nov 2023NT$1.4tNT$225.3bNT$8.2b25.2x165.5x6x
Sat, 30 Sep 2023NT$1.4tNT$225.2bNT$8.2b25.6x167.2x6.1x
Mon, 28 Aug 2023NT$1.4tNT$225.3bNT$8.5b24.9x160.1x6x
Wed, 26 Jul 2023NT$1.5tNT$227.0bNT$11.5b25.5x127.1x6.4x
Fri, 23 Jun 2023NT$1.4tNT$226.5bNT$11.6b24.4x121.6x6.2x
Sun, 21 May 2023NT$1.4tNT$222.3bNT$12.5b24.3x112.6x6.3x
Tue, 18 Apr 2023NT$1.5tNT$219.7bNT$12.3b23.3x120x6.7x
Thu, 16 Mar 2023NT$1.4tNT$216.2bNT$13.0b21.4x107.2x6.4x
Sat, 11 Feb 2023NT$1.4tNT$214.5bNT$13.8b21.6x102.7x6.6x
Mon, 09 Jan 2023NT$1.3tNT$214.5bNT$13.8b19.7x94x6.1x
Price to Earnings Ratio

94x


Total Market Cap: NT$1.3tTotal Earnings: NT$13.8bTotal Revenue: NT$214.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Taiwanese Healthcare Sector Price to Earnings3Y Average 188.5x202420252026
Current Industry PE
  • Investors are pessimistic on the Taiwanese Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 123x which is lower than its 3-year average PE of 188x.
  • The industry is trading close to its 3-year average PS ratio of 6.4x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have remained mostly flat over the last three years.
  • Meanwhile revenues for these companies have grown 7.6% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, profits have held steady.

Industry Trends

Which industries have driven the changes within the Taiwanese Healthcare sector?

TW Market2.14%
Healthcare-0.93%
Healthtech0.88%
Pharma-0.16%
Healthcare Services-0.65%
Biotech-1.34%
Life Sciences-2.20%
Medical Equipment-2.29%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio of 17.1x.
    • Analysts are expecting annual earnings decline of 13.5%, which is less than its past year's earnings decline of 28.5%.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 88% over the next 5 years.
  • This is better than its past earnings growth rate of 4.2% per year.
  • In contrast, the Healthtech industry is expected to see its earnings decline by 14% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
4123 Center LaboratoriesNT$41.6012.3%
+NT$3.4b		1.5%PE17.5x
6535 Lumosa TherapeuticsNT$194.505.4%
+NT$1.7b		-18.3%PS769.4x
1795 Lotus PharmaceuticalNT$283.001.6%
+NT$1.2b		6.2%PE15.7x
4157 TaiGen Biopharmaceuticals HoldingsNT$13.4010.7%
+NT$925.4m		18.6%PS246.2x
6550 Polaris GroupNT$31.103.0%
+NT$693.4m		-31.6%PS338.3x

Latest News

6446
NT$470.00
PharmaEssentia
7D
-4.1%
1Y
-13.4%
6550
NT$31.10
Polaris Group
7D
3.0%
1Y
-31.6%
1795
NT$283.00
Lotus Pharmaceutical
7D
1.6%
1Y
6.2%

1795: Southeast Asia Presbyopia Franchise Will Drive Future Share Price Upside

Analysts have modestly reaffirmed their outlook on Lotus Pharmaceutical, keeping the target price effectively unchanged at around $395.20, as stable fair value estimates, discount rate assumptions, and forecasts for revenue growth, profit margins, and future P/E collectively support a steady valuation profile. What's in the News Lotus Pharmaceutical and LENZ Therapeutics submitted a New Drug Application to South Korea's Ministry of Food and Drug Safety for VIZZ, an eye drop treatment for presbyopia in adults.
4743
NT$55.60
Oneness Biotech
7D
-4.1%
1Y
-35.4%
6472
NT$488.00
Bora Pharmaceuticals
7D
-0.9%
1Y
-21.0%

6472: Alliance With Corealis Will Support Stronger Long Term Performance

Analysts have modestly reiterated their outlook on Bora Pharmaceuticals, keeping the fair value estimate steady at $788.87 per share, as they see no material changes to projected revenue growth, margins, or valuation multiples. What's in the News Bora Pharmaceuticals and Corealis Pharma formed a strategic alliance to deliver integrated end to end oral solid dose development and manufacturing services, giving clients a single pathway from early formulation through commercial production (company announcement) The partnership combines Bora's global commercial infrastructure with Corealis' formulation and clinical scale manufacturing expertise, aiming to accelerate timelines and reduce complexity for biotech and pharma innovators (company announcement) Bora and Corealis will align project management and quality systems across the drug development lifecycle to lower outsourcing risk and improve reliability from discovery through commercial launch (company announcement) Valuation Changes Fair Value Estimate is unchanged at NT$788.87 per share, indicating no revision to Bora Pharmaceuticals' intrinsic value assessment.
6919
NT$155.00
Caliway Biopharmaceuticals
7D
-1.6%
1Y
164.5%
4157
NT$13.40
TaiGen Biopharmaceuticals Holdings
7D
10.7%
1Y
18.6%
6541
NT$55.00
Tanvex BioPharma
7D
-5.0%
1Y
-15.0%
7799
NT$451.50
Heron Neutron Medical
7D
-6.9%
1Y
125.8%
6461
NT$17.80
Intech Biopharm
7D
21.1%
1Y
-32.4%
4123
NT$41.60
Center Laboratories
7D
12.3%
1Y
1.5%
6949
NT$342.50
Pell Bio-Med Technology
7D
-4.6%
1Y
328.1%
6491
NT$285.00
Pegavision
7D
1.8%
1Y
-25.0%
6535
NT$194.50
Lumosa Therapeutics
7D
5.4%
1Y
-18.3%
7729
NT$60.10
Steminent Biotherapeutics
7D
17.4%
1Y
170.7%
6467
NT$111.50
Taho Pharmaceuticals
7D
-10.4%
1Y
125.3%